BNT324
BNT324 is an experimental antibody-drug conjugate from BioNTech SE in phase 3 trials for prostate cancer and non-small-cell lung cancer, aimed at B7-H3.
Overview
BNT324 (DB-1311) is an antibody-drug conjugate developed by BioNTech SE. Its target is B7-H3 (the sponsor names B7-H3). The sponsor states: BNT324 (DB-1311) is an antibody-drug conjugate targeting B7-H3, given as an intravenous infusion in 21-day cycles; a phase 3 trial compares it with docetaxel in metastatic castration-resistant prostate cancer. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT07365995 (A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer), in prostate cancer and non-small-cell lung cancer. The largest, NCT07365995, plans to enrol 736 participants with primary completion expected 2031-02. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.
- AmivantamabApproved
- CamizestrantApproved
- Comprehensive genomic profilingStandard of care
- Liquid biopsy (ctDNA)Standard of care
- LorlatinibApproved
- MRD / molecular residual disease testingEstablished
- ADC payload neutralisersPhase 1
- BGB-16673Phase 3
- Bispecific ADCPhase 3
- BRUIN CLL-321Positive
- CaDAnCe-304Recruiting
- CIRCULATE-Japan (GALAXY / VEGA / ALTAIR)Active
- A clone report from blood at every treatment cycle
- A fast route to the matched drug when it is licensed for another cancer
- A multi-cancer platform trial of adaptive (dose-holiday) therapy
- A national rapid research autopsy network for end-stage cancer
- A standard evolvability score for every tumour
- A standing platform trial that assigns treatment by how the tumour escaped
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance atlas · Lines of therapy.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials
Latest papers
topQuery for this drug: (TITLE:"BNT324" OR ABSTRACT:"BNT324" OR TITLE:"DB-1311" OR ABSTRACT:"DB-1311") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about BNT324, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentQLC5508
Shares B7-H3, Prostate cancer, Non-small-cell lung cancer and the tags pipeline, ctgov-ingest.
- TreatmentBCB-276
Shares B7-H3 and the tags pipeline, ctgov-ingest.
- TreatmentYL201
Shares B7-H3, Prostate cancer, Non-small-cell lung cancer and the tags pipeline, ctgov-ingest.
- TreatmentBNT113
Shares BioNTech and the tags pipeline, ctgov-ingest.
- TreatmentPM8002
Shares BioNTech, Non-small-cell lung cancer and the tags pipeline, ctgov-ingest.
- TreatmentPF-07248144
Shares Prostate cancer, Non-small-cell lung cancer and the tags pipeline, ctgov-ingest.
- TreatmentAglatimagene besadenovec
Shares Prostate cancer, Non-small-cell lung cancer and the tags pipeline, ctgov-ingest.
- TreatmentCetrelimab
Shares Prostate cancer, Non-small-cell lung cancer and the tags pipeline, ctgov-ingest.